Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, variant U1 small nuclear 3 (RNVU1-3) is a non-coding small nuclear RNA (snRNA) belonging to the U1 snRNA variant family, which are encoded by "class I pseudogenes" of U1 snRNA in the human genome. Like canonical U1 snRNA, variant U1 (vU1) molecules participate in the spliceosome, a complex responsible for precise removal of introns from pre-mRNA during gene expression. Although vU1s were once believed to be non-functional pseudogenes, recent work demonstrates that many are transcribed, processed, incorporated into RNP complexes, and regulate alternative splicing or mRNA processing for specific gene subsets, particularly during development or in specific tissues. Each vU1 has unique sequence differences; however, not all have the same functional capacity as canonical U1 snRNA, and their impact is often subtler or context-dependent. There is currently no evidence that RNVU1-3 is used as a specific drug target or disease biomarker.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, variant U1 small nuclear 3 (RNVU1-3).